Form 8-K - Current report:
SEC Accession No. 0001558370-23-002942
Filing Date
2023-03-06
Accepted
2023-03-06 17:04:29
Documents
13
Period of Report
2023-03-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mxct-20230306x8k.htm   iXBRL 8-K 38496
2 EX-99.1 mxct-20230306xex99d1.htm EX-99.1 35697
  Complete submission text file 0001558370-23-002942.txt   205022

Data Files

Seq Description Document Type Size
3 EX-101.SCH mxct-20230306.xsd EX-101.SCH 3002
4 EX-101.LAB mxct-20230306_lab.xml EX-101.LAB 16576
5 EX-101.PRE mxct-20230306_pre.xml EX-101.PRE 10715
7 EXTRACTED XBRL INSTANCE DOCUMENT mxct-20230306x8k_htm.xml XML 4969
Mailing Address 22 FIRSTFIELD ROAD SUITE 250 GAITHERSBURG MD 20878
Business Address 22 FIRSTFIELD ROAD SUITE 250 GAITHERSBURG MD 20878 301-517-5556
MAXCYTE, INC. (Filer) CIK: 0001287098 (see all company filings)

EIN.: 522210438 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40674 | Film No.: 23709777
SIC: 8731 Services-Commercial Physical & Biological Research